In 46 states, once you choose Medicare Advantage at 65, you can almost never leave.
Medicare
Posted inHealth and Social Policy
We May Not Negotiate Prices for Ten Drugs After All
Rules that exempt drugs from Medicare negotiation if there’s ‘meaningful’ generic competition could whittle down the effect of the program.
Posted inHealth and Social Policy
Medicare Price Negotiation: Ten Drugs That Made the List, and Ten That Should Have
Advocates were thrilled that Medicare will negotiate the price of several insulins. But other high-profit drugs are protected by the new program’s rules.
Posted inHealth and Social Policy
Pricing a Lifesaving Drug
Will Medicare use its ample leverage to make Wegovy affordable?
Posted inMoney, Politics, and Power
Who’s Running Big Pharma’s Last Stand Against Slightly Fairer Drug Pricing
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short.
Posted inHealth and Social Policy
Health Care’s Intertwined Colossus
How decades of policy failures led to the ever-powerful UnitedHealth Group
Posted inHealth and Social Policy
Patient Zero
Tom Scully is as responsible as anyone for the way health care in America works today.
Posted inHealth and Social Policy
A Sick System
The business of health care in America is deeply out of whack.
Posted inTAP
The Pro-Corporate New York Times
Today on TAP: Its coverage is often biased and sloppy.
Posted inHealth and Social Policy
Merck Says Negotiating Drug Prices Is Unconstitutional
The Inflation Reduction Act took minor steps against Big Pharma price-gouging. Merck is outraged.
